We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.67%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$666M
AUM Growth
-$78.6M
(-11%)
Cap. Flow
+$47.8M
Cap. Flow
% of AUM
7.17%
Top 10 Holdings %
Top 10 Hldgs %
3.73%
Holding
1,985
New
628
Increased
360
Reduced
345
Closed
644
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$3.83M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$3M |
| 3 |
Teck Resources
TECK
|
+$2.87M |
| 4 |
MODV
ModivCare
MODV
|
+$2.67M |
| 5 |
Genpact
G
|
+$2.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.07M |
| 2 |
CHS
Chicos FAS, Inc.
CHS
|
+$2.68M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$2.45M |
| 4 |
Crane NXT
CXT
|
+$2.44M |
| 5 |
ATCO
Atlas Corp.
ATCO
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.12% |
| 2 | Technology | 15.11% |
| 3 | Consumer Discretionary | 12.76% |
| 4 | Industrials | 12.53% |
| 5 | Financials | 11.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NWLI
701
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $365K | 0.05% |
1,801
-1,006
| -36% | -$206K |
|
702
TFS Financial
TFSL
$4.93B
| $364K | 0.05% |
26,527
-10,513
| -28% | -$155K |
|
|
CWEN.A
703
DELISTED
Clearway Energy Class A
CWEN.A
| $363K | 0.05% |
11,362
+3,537
| +45% | +$110K |
|
704
TETRA Technologies
TTI
$1.26B
| $363K | 0.05% |
89,471
-235,133
| -72% | -$1.04M |
|
705
Weatherford International
WFRD
$6.22B
| $363K | 0.05% |
+17,170
| New | +$547K |
|
706
Core Laboratories
CLB
$521M
| $362K | 0.05% |
+18,259
| New | +$485K |
|
707
Veeco
VECO
$3.23B
| $362K | 0.05% |
18,652
-4,081
| -18% | -$90.5K |
|
|
UBX
708
DELISTED
Unity Biotechnology
UBX
| $361K | 0.05% |
63,994
-8,426
| -12% | -$70.3K |
|
709
ATI
ATI
$31B
| $360K | 0.05% |
15,862
-15,057
| -49% | -$397K |
|
710
Resources Connection
RGP
$145M
| $360K | 0.05% |
17,680
-23,547
| -57% | -$420K |
|
711
SFL Corp
SFL
$1.61B
| $360K | 0.05% |
37,963
-41,597
| -52% | -$433K |
|
|
ORTX
712
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $360K | 0.05% |
61,640
+24,212
| +65% | +$137K |
|
713
Graphic Packaging
GPK
$3.58B
| $359K | 0.05% |
+17,517
| New | +$370K |
|
714
Calix
CALX
$2.39B
| $357K | 0.05% |
10,445
-1,849
| -15% | -$68.7K |
|
715
InterDigital
IDCC
$8.89B
| $357K | 0.05% |
5,866
+1,422
| +32% | +$87.2K |
|
716
CONMED
CNMD
$1.47B
| $356K | 0.05% |
+3,718
| New | +$446K |
|
717
Terex
TEX
$7.74B
| $356K | 0.05% |
+13,003
| New | +$433K |
|
718
Senseonics Holdings Inc
SENS
$366M
| $353K | 0.05% |
17,146
+5,909
| +53% | +$154K |
|
719
Axcelis
ACLS
$4.33B
| $352K | 0.05% |
6,424
-4,676
| -42% | -$271K |
|
720
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$5.2B
| $352K | 0.05% |
+9,301
| New | +$370K |
|
721
Methode Electronics
MEI
$592M
| $352K | 0.05% |
+9,502
| New | +$410K |
|
|
SNV
722
DELISTED
Synovus
SNV
| $352K | 0.05% |
+9,772
| New | +$404K |
|
|
GOOD
723
Gladstone Commercial Corp
GOOD
$627M
| $351K | 0.05% |
18,619
-4,979
| -21% | -$101K |
|
724
BioXcel Therapeutics
BTAI
$27.8M
| $350K | 0.05% |
+1,658
| New | +$349K |
|
725
Corcept Therapeutics
CORT
$12B
| $350K | 0.05% |
14,704
+2,891
| +24% | +$63K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, GSA Capital Partners held 1,985 positions worth $666M, down 11% from $745M the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.
GSA Capital Partners deployed $47.8M of net new capital in Q2 2022, opening 628 new positions and adding to 360 existing holdings. Its largest new stake was Relay Therapeutics: 178,593 shares worth $2.99M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Chicos FAS, Inc., an estimated $2.68M trimmed.
- GSA Capital Partners's largest Q2 2022 buy was Relay Therapeutics: 178,593 shares worth $2.99M.
- GSA Capital Partners added most to Genpact in Q2 2022, an estimated $2.6M increase.
- GSA Capital Partners's biggest Q2 2022 reduction was Chicos FAS, Inc., cutting an estimated $2.68M.
- GSA Capital Partners fully exited Amazon in Q2 2022, selling an estimated $3.07M.
- GSA Capital Partners's ten largest holdings make up 3.7% of its $666M portfolio in Q2 2022.
- GSA Capital Partners opened 628 new positions and closed 644 in Q2 2022.
- GSA Capital Partners's portfolio value fell 11% quarter-over-quarter to $666M.
Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.